Alzamend Neuro
ALZN
13 hedge funds and large institutions have $723K invested in Alzamend Neuro in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
62% more capital invested
Capital invested by funds: $447K → $723K (+$276K)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
11.47% more ownership
Funds ownership: 6.46% → 17.93% (+11%)
0% more funds holding
Funds holding: 13 → 13 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.3K |
| 2 |
Citigroup
New York
|
+$10.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.2K |
| 4 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$212K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$40.1K |
| 3 |
VF
Virtu Financial
New York
|
-$23K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.7K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$78 |
ALZN Hedge Fund Activity: Q1 2026 in Review
13 of the 8,205 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q1 2026, worth a combined $723K — up 62% from $447K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ALZN positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $36.3K. The largest seller was DRW Securities, exiting entirely with an estimated $212K sold.
- 13 institutional investors held Alzamend Neuro (ALZN) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $723K of Alzamend Neuro stock for Q1 2026, up 62% quarter-over-quarter.
- 5 funds opened new Alzamend Neuro positions in Q1 2026 and 4 closed out, a net change of +1 holder.
- The largest Alzamend Neuro buyer in Q1 2026 was Geode Capital Management, an estimated $36.3K added.
- The largest Alzamend Neuro seller in Q1 2026 was DRW Securities, an estimated $212K sold.
Based on aggregated 13F filings for Q1 2026.